A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients with Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

The purpose of this study is to help Arcus Biosciences, Inc. (the Sponsor) understand whether study drugs domvanalimab (also called AB154) plus zimberelimab (also called AB122) are safe and effective when given together with and without standard of care chemotherapy (FOLFOX) to patients with the type of cancer you have. Domvanalimab and zimberelimab are considered as immunotherapy. This type of treatment works by blocking a protein (programmed death-ligand 1, or PD-L1) that can cause tumors to grow. By blocking this protein, the study drugs may cause your cancer to stop growing or shrink. These study drugs are investigational meaning they are not approved by the United States Food and Drug Administration (US FDA), or any other agencies like the US FDA, to treat your cancer.

Are you Eligible? (Inclusion Criteria)

• You must be 18 years of age or older.
• You must have been diagnosed with advanced cancer in the upper gastroinestinal tract.
• You must be comfortable receiving the study drug through a vein.